In women with platinum-sensitive relapsed ovarian cancer, maintenance therapy with olaparib does not provide a significant overall survival benefit, but long-term therapy is possible, according to an updated analysis of a randomized, double-blind phase II study.
Consideration of clinical trial data and anecdotal patient information can help oncologists weigh available treatment options to either help delay disease progression or avoid hormone therapy for patients with oligometastatic prostate cancer.
In women with platinum-resistant or platinum-refractory recurrent ovarian cancer, health-related quality of life appears to predict early cessation of chemotherapy and shorter overall survival, and is more sensitive than ECOG performance status, based on an international prospective cohort study.
Drs. Christodouleas, Jason Efstathiou, and Libni Eapen discuss the recent advances in adjuvant radiation for the treatment of locally advanced bladder cancer and NRG Oncology’s NRG-GU001 clinical trial.
ASCO issued an endorsement for the European Association of Urology’s guideline on muscle-invasive and metastatic bladder cancer, including recommendations on multidisciplinary care, chemo- and radiotherapy, and other management issues.
Dr. George J. Bosl will receive the ASCO Distinguished Achievement Award for his pioneering work in research and patient care dealing with the management of testicular cancer and other genitourinary cancers.
Ovarian function suppression has the potential to affect fertility, however providers should be aware of the role of adjuvant therapy and other interventions in helping patients maintain bone density and reduce fracture risk.
ASCO published guidelines and endorsements addressing myriad aspects of prostate cancer care, including radiotherapy in men after prostatectomy, hormone therapy and chemotherapy, and survivorship care.
Learn more about the inaugural year of the Maintenance of Certification (MOC) Self-Assessment Activity at the 2015 Genitourinary Cancer Symposium through an interview with participant Dr. Elizabeth Guancial.
Arguments for treating men with castration-resistant prostate cancer early or late were provided based on data from CHAARTED and GETUG-AFU 15. In addition, the use and sequencing of Ra 223 were also provided based on analyses from ALSYMPCA and datasets from clinical practice.
One year of neratinib improved the rate of invasive disease-free survival compared to placebo in patients with HER2-positive early stage breast cancer who had undergone prior adjuvant therapy with chemotherapy and trastuzumab, according to results of a randomized phase III trial.
Treatment with the Wee1 inhibitor AZD1775 plus carboplatin showed encouraging antitumor activity in patients with p53-mutated ovarian cancer that is refractory or resistant to standard first-line therapy.
The randomized phase III TOAD trial investigated whether immediate intervention with androgen deprivation therapy would improve overall survival compared with delayed androgen deprivation therapy in patients with prostate cancer.